Insider Selling: Medifast (NYSE:MED) Director Sells $111,951.12 in Stock

Medifast Inc (NYSE:MED) Director Daniel Chard sold 9,544 shares of the firm’s stock in a transaction on Tuesday, September 29th. The shares were sold at an average price of $11.73, for a total value of $111,951.12. Following the completion of the sale, the director directly owned 130,609 shares of the company’s stock, valued at approximately $1,532,043.57. This trade represents a 6.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Medifast Stock Performance

Shares of NYSE MED opened at $11.73 on Friday. The firm has a market capitalization of $131.14 million, a P/E ratio of -5.03 and a beta of 0.68. Medifast Inc has a one year low of $9.22 and a one year high of $14.15. The company’s fifty day moving average is $11.75 and its two-hundred day moving average is $11.35.

Medifast (NYSE:MED) last posted its quarterly earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.37. The business had revenue of $76.38 million for the quarter, compared to analysts’ expectations of $72.70 million. Medifast had a negative net margin of 8.08% and a negative return on equity of 6.69%. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. On average, sell-side analysts forecast that Medifast Inc will post -1.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on MED. Zacks Research cut shares of Medifast from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 11th. Weiss Ratings raised Medifast from a “sell (e+)” rating to a “sell (d)” rating in a research note on Monday, August 17th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Medifast currently has a consensus rating of “Reduce” and a consensus price target of $12.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. State of Wyoming boosted its position in shares of Medifast by 19.8% in the 1st quarter. State of Wyoming now owns 6,646 shares of the specialty retailer’s stock worth $68,000 after buying an additional 1,097 shares in the last quarter. Ancora Advisors LLC acquired a new stake in Medifast in the 2nd quarter valued at about $75,000. Ieq Capital LLC purchased a new position in Medifast during the 2nd quarter valued at about $114,000. Squarepoint Ops LLC purchased a new position in Medifast during the 2nd quarter valued at about $214,000. Finally, Chico Wealth RIA acquired a new position in Medifast during the second quarter worth about $223,000. Institutional investors and hedge funds own 95.51% of the company’s stock.

About Medifast

Medifast, Inc (NYSE: MED) is a health and wellness company that provides weight-management and healthy-lifestyle products and programs. Its principal brand is OPTAVIA, which offers structured plans designed to support weight loss, nutrition, and long-term habit development.

The company’s product portfolio includes meal-replacement shakes, bars, snacks, entrees, beverages, supplements, and other packaged “Fuelings.” Medifast also supports customers through independent OPTAVIA Coaches, who provide guidance, accountability, and lifestyle support through the company’s direct-selling model.

Founded in 1980, Medifast serves customers primarily in the United States through its e-commerce and direct-to-consumer channels.